GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Earnings per Share (Diluted)

Verici Dx (LSE:VRCI) Earnings per Share (Diluted) : £-0.05 (TTM As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Earnings per Share (Diluted)?

Verici Dx's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £-0.03. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.

Verici Dx's EPS (Basic) for the six months ended in Jun. 2023 was £-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.

Verici Dx's EPS without NRI for the six months ended in Jun. 2023 was £-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.05.


Verici Dx Earnings per Share (Diluted) Historical Data

The historical data trend for Verici Dx's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Earnings per Share (Diluted) Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Earnings per Share (Diluted)
- -0.04 -0.06

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Earnings per Share (Diluted) -0.01 -0.03 -0.03 -0.03 -0.03

Competitive Comparison of Verici Dx's Earnings per Share (Diluted)

For the Diagnostics & Research subindustry, Verici Dx's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's PE Ratio distribution charts can be found below:

* The bar in red indicates where Verici Dx's PE Ratio falls into.



Verici Dx Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Verici Dx's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.365-0)/164.668
=-0.06

Verici Dx's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-4.176-0)/170.319
=-0.02

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Verici Dx  (LSE:VRCI) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Verici Dx Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Verici Dx's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (LSE:VRCI) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (LSE:VRCI) Headlines

No Headlines